Introduction
============

Hepatitis C virus (HCV) is a blood-borne hepatotropic member of the Flaviviridae that can establish end-stage liver diseases. It is estimated that more than 185 million people are persistently infected worldwide (Petruzziello et al., 2016). Regarding the full sequence analysis, HCV has been classified into at least 7 genotypes and a number of sub-genotypes (Khodabandehloo and Roshani, 2014).

Hepatitis C virus therapy has been facing a revolution following the discovery of direct-acting antiviral drugs (DAAs) that leads the highest rate of sustained virologic response ever (Paolucci et al., 2013). However, one of the main problems with anti-HCV DAAs generation is the presence of natural resistant variants which arise spontaneously (Jindal et al., 2017). These variations may lead to virological response failure during HCV treatment. Thus, an early evaluation of the DAAs resistance could be beneficial to prevent treatment failure and to improve the HCV therapy management.

Three classes of DAAs are candidates of marketing nowadays that among them telaprevir, boceprevir and glecaprevir are NS3 protease inhibitors (PIs) (Lamb, 2017; Morsica et al., 2017). PIs drugs inhibit NS3 protease activity by occupying the activation site or surrounding motifs, consequently inhibiting HCV viral replication (Lamb, 2017). *NS3* protease is a very attractive target for HCV therapy by synthesized protease inhibitors (PIs), however natural appearance of variability in NS3 protease sequence influences its susceptibility to these drugs.

The enzymatic protease activity of NS3 protein mapped to 189 amino acids from its amino-termini (Courcambeck et al., 2006; Khanlari et al., 2014). This activity has postulated to be involved in some HCV pathogenesis such as fibrogenesis and immune suppression (Khanlari et al., 2014; Khanizadeh et al., 2016). The error-prone property of RNA-dependent RNA polymerase (RDRP) of HCV, introduces some substitutions in virus sequence during replication (Courcambeck et al., 2006; Bartels et al., 2008). Actually, this kind of diversity induces the expansion of natural drug resistance strains before the start point of therapy(Bartels et al., 2008). The natural and pre-existing drug resistance substitutions in the protease region have been reported in a couple of reports (Bartels et al., 2008; Paolucci et al., 2012; Vicenti et al., 2012; Zeminian et al., 2013; Jindal et al., 2017). There are different well-defined substitutions alongside the protease region that are responsible for PIs resistant, including *V36L*, *T54S*, *V55A*, *Q80H*, *R155K*, *A156S* and *V170A*and *V36M* which may affect the therapy response (Vallet et al., 2011; Jindal et al., 2017; Martinez et al., 2017).

In our country, there are limited studies that considered PIs mutations. Afrasiabi et al; interestingly found the critical *V36L* and *R155K* substitutions among a small population (7 patients) when analyzed by clonal sequencing (Afrasiabi et al., 2015). However, regarding this finding, a conclusion about the rate of natural *PIs*mutations in our patient population is far to be reached. Furthermore, screening of the natural substitutions of protease is critical based on their cost and effectiveness (Lopez-Labrador et al., 2008; Romano et al., 2010).

Therefore, the aim of this study was to investigate the sequence of the protease region of *NS3* from HCV-infected patients who did not respond to standard IFN+Ribavirin therapy. For this purpose, the *NS3* protease sequence of 14 non-responder patients to standard IFN+Ribavirin therapy was analyzed by simple sequencing method and to ensure the fidelity, some of them were also subjected to clonal-sequencing as well. This investigation revealed a low frequency of mutations related to PIs reduced sensitivity but not PIs resistance in samples.

Materials and Methods
=====================

*Patients*

A total of 14 confirmed chronic HCV patients that have not responded to standard Interferon+Ribavirine therapy (named as IFN/RIB Non-responder) or relapsed afterwards, were selected from the Liver Clinic of Shahid Motahari Clinic (Shiraz, Iran), in 2016. The IFN/RIB Non-responders were selected due to their priority for taking DAA medications such as protease inhibitors regarding the liver specialist advice. All patients had fulfilled a course of standard peg-interferon/ribavirin therapy, but no PIs drug consumption. Also, they were negative for HIV and HBV infection based on their medical records. To determine the sample size, we considered α and β as 0.05 and =0.2, respectively. Also, the power of our test was PASS.

The Ethics Committee affiliated with Shiraz University of Medical Sciences has approved the study and written informed consent was obtained from all the participants before sampling. Blood samples were taken in tubes and serum parts were collected in sterile condition, and were stored at -70°C until further tests.

*Primer Design*

At first, the reference HCV genotypes and subtypes (those with *genotype 1a*, *1b*, or *3a*) full length sequences, were retrieved from NCBI (National Center for biotechnology Information) and the LOS Alamos database. Then, multiple sequence alignments were performed by Mega7 software. The primer sequences covering 203 amino acids from the protease region of *NS3*, were designed by Oligo7 and primer3 software so that they can detect the sequences associated with *genotype 1a*, *1b* and *3a*. The primers are listed in [Table 1](#T1){ref-type="table"}.

*HCV genome detection in serum samples*

Before starting the amplification of NS3 sequence of samples, the presence of *HCV* genome was evaluated by an in-house nested PCR assay, as described before (Afrasiabi et al., 2015). It was performed by specific pairs of primers targeting 5/noncoding region, NCR. These primers were designed to amplify the early 5/NCR region of all HCV genotypes.

![The Gel Electrophoresis Analysis of Different Nested-PCRs. A, The presence of a 700 bp band in samples 1 and 2 were indicative of amplification of samples with 1a sub-genotypes; B, The appearance of a 600bp band in line 1, 2 and 3 were indicative of positivity of these samples for sub-genotype 1b; C, The presence of a 600bp band in line 1, 2, 3, and 4 was a marker of sub-genotype 3a. The size marker was 100 bp ladder (Cinnaclone Inc.)](APJCP-20-2311-g001){#F1}

![The Phylogenetic Analysis of 14 Samples based on NS3 Protease Region. All the samples including two 1a, three 1b and nine 3a sub-genotypes were correctly distributed into relevant clusters of tree by the help of neighbor-joining method. The investigated samples were highlighted by black circles in the constructed tree. The values on internal nodes are showing the percentage of reliability, bootstrapping value](APJCP-20-2311-g002){#F2}

![The Multiple Sequences Alignment of All Investigated Samples. The multiple alignment of new sequences with reference Hepatitis C virus sequences revealed different uncharacterized mutations and few substitutions responsible for PIs drug resistance. There are some other mutations that discussed in the text. Samples are nominated as ShrNJ-NS3 with a suffix of sample number](APJCP-20-2311-g003){#F3}

###### 

Designed Primers for Amplification of 3 Subgenotypes 1a, 1b and 3a

  Primer Name            \*Sequence 5' - 3'        Application
  ---------------------- ------------------------- -----------------------------------------------------
  NJ-Com A1 (Forward)    ATCACVTGGGGVGCRGAYAC      First round amplification (all genotypes)
  NJ-Com A2 (Reverse)    AACTTRCCRTAGGTGGARTABGT   First round amplification (all genotypes)
  NJ-In a1 (Forward)     CGAYGGAATGGTCTCCAAG       Second amplification (specialized for genotype 1a)
  NJ-In a2 (Reverse)     CRGCAACRGAGGGGTTGAG       Second amplification (specialized for genotype 1a)
  NJ-In b1 (Forward)     GGCCTRCTTGGYTGCATCAT      Second amplification (specialized for genotype 1b)
  NJ-In b2 (Reverse-1)   GTAGRTGGGCCACTTGAAAT      Second amplification (specialized for genotype 1b)
  NJ-In b3 (Reverse-2)   TYAGGACGAGYACCTTGTA       Second amplification (specialized for genotype 1b)
  NJ-F3a (Forward)       GGGCCTTYTTGGGACTATTG      Second amplification (specialized for genotype 3a).
  NJ-R3a (Reverse)       GGGACCTTTGTGCTYTTRCC      Second amplification (specialized for genotype 3a).

###### 

The Substitutions and Their Frequency in Sample Sequences. The more prevalent substitutions were indicated by underline marker and PIs resistance mutations were bolded

  Genotype         Variations
  ---------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1a and 1b(N=5)   S7A(3), Q9R, T10W, R11F, Q28R, V48I(2), V51A, K62R, A66G(3), P67A, T72N, P86Q/A(3), K87A(3), Q89P, R117C, V132I(2), F147S/A(4), A150V, I153L, V170I(3), N174S(2)
  3a(N=9)          T16A , N27D , T30A , S37Y , A39T(3), I52M(9), A67V(3), P89S , A98T(6), S102A(9), V107I , L132I(2), A133S, A151V, S166A(8), V170I(8), T177S , A179T

*Amplification of NS3 Protease Region*

Viral RNA was extracted from the serum samples using an RNA extraction kit (Stratec inc., Germany), according to the instruction. Then, complementary DNA (cDNA) synthesis and first amplification reaction were performed on viral RNA using the commercially available kit (Onestep cDNA synthesis Takara kit, Takara Inc,. Japan), and common primers targeting protease region of all sub-genotypes (*NJ-Com A1* and *NJ-Com A2* pair of primers) based on the recommended instructions. After this, a nested-PCR was performed with the help of one of specific *NJ-In a1*, *NJ-In b1*, and *NJ-F3a* forward primers and a common *NJ-ComA2* reverse primer to amplify sequences from genotype 1a, 1b and 3a, respectively. Nested-PCR steps were including a primary denaturation at 94°C for 4 minutes, then, 35 cycles of denaturation at 94°C for 40 seconds, annealing at 51°C for 40 seconds and extension at 72°C for 45 seconds; In the end, the desired product sequences were purified from agarose gel, in accordance with the manual of the gel extraction kit (MACHERY-NAGEL(MN), Germany).

*Cloning and Sequencing*

In order to enhance the sensitivity of variation detection in *NS3* sequence, some of them cloned into vector then introduced into sequencing. In this step, the purified PCR product was cloned using TA/cloning system kit (CinnaGen Inc., Iran) containing linear vector *pTG19-T*. Following the kit instructions, ligation was performed using T4 ligase enzyme at 37°C. Then, the reaction product was transformed into competent DH5α bacteria. The bacteria were grown on LB agar, containing ampicillin (50 µg/mL) along with X-Gal and IPTG. Recombinant true plasmids were initially screened by blue/white screening. Purification of true recombinant plasmids was done using Plasmid DNA Purification kit, based on the recommended instruction (MACHEREY-NAGEL Company, Germany). For each patient, nearly 3 colonies of plasmids were sent for sequencing (Eurofins Genomics Company., Germany), which were performed bidirectional using *NJ-In a1* or *NJ-In b1* or *NJ-F3a* and *NJ-Com A1* primers set.

*Sequence variation Analysis and Phylogeny*

The NS3 sequence of different reference genotypes of HCV was retrieved from NCBI database, then, aligned using MEGA7 software. The employed reference sequences accession numbers for further analysis were as follows: *genotype 1a*, *NC004102*, *D10749* and *DQ068207*; *genotype 1b*, *AY460204*, *U01214*, and *AF176573*; *genotype 1C*, *AY651061* and *D14853*; *genotype 2*, *AY746460* and *AF169005*; genotype 3a, *D28917*; *genotype 4*, *Y11604*; *genotype 5*, *AF064490*; and *genotype 6*, *Y12083*.

The sequencing results were retrieved through Chromas software, and were then multiple aligned by the help of Clustal W method, using Mega7 software. The variations responsible for PIs resistance were detected by comparing with reference sequences. In the other word, for substitution analysis, the major well-defined amino acid residues responsible for "complete PIs resistance", including *V36*, *T54*,*V55*, *Q80*, *R155*, *A156*, *D168* and *I/V170* as well as those attributed to "potential resistance" such as *F43*, *Y56*, *V107*, *R117*, *S122* and *S174* were considered (Sargin Altunok et al., 2016; Zhang et al., 2016). Hence, the sequencing results were also submitted to geno2pheno online analysis system to detect substitutions with PIs resistance importance. In this regard, substitutions categorized as "resistance" or "reduced sensitivity" mutations as described before (Kalaghatagi et al,. 2016). This system was also employed to confirm the genotypes of investigated samples as well.

Furthermore, as HCV samples were pre-defined in the case of genotype, they were investigated if those commercial genotyping assay could be compatible with phylogenetic analysis of protease sequence. For this purpose, Phylogenic tree was constructed by the neighbor-joining method using MEGA7 software. Finally, the created tree was evaluated by 500 times bootstrapping to ensure its fidelity.

Results
=======

*Patients*

The mean age of subjects was 46.6 ± 12.3 years with a range of 29-66 years. The gender of 10 participants was men and 4 others were women.

*The virus infection screening*

In order to screen the virus genome presence, nested PCR was employed to target 5´NTR region. The test was positive for all enrolled serum samples. A band with near 240 bp length was demonstrative of the virus presence in all samples after electrophoresis analysis. These 14 positive samples were included in the next step of analysis in protease sequence.

*Protease region amplification*

The new designed Nested PCR for amplification of NS3 protease showed suitable results in three different *genotypes, 1a*, *1b* and*3a*. The electrophoresis analysis demonstrated that for *genotypes 1a*, *1b*, and *3a* different bands with 700, 600 and 600 bp lengths were detectable, respectively as demonstrated in [Figure 1](#F1){ref-type="fig"}.

*The Cloning Results*

The colony PCR assay was performed to ensure that the insertion of amplified protease region targets into plasmids. Regarding these results, the majority of white colonies were harboring recombined positive plasmids in spite of the ones with the blue color. Hence, out of 5 positive colonies that have been submitted for sequencing, 3 sequencing results were reliable and useful.

*Sequence analysis showed a low frequency of PIs potential resistance substitution*

The substitutions in amino acids sequence showed a relative conserve property in this region. However, some uncharacterized variations and few mutations responsible for potential resistance but not complete resistance was identified following the sequence analysis, as depicted in [Figure 3](#F3){ref-type="fig"} and [Table 2](#T2){ref-type="table"}

Among mutations with PIs resistance importance, only 1 out of 14 samples (7%) *harbored R117C+N174S* double mutation, which would causes reduced susceptibility to Telaprevir. It belong to a genotype 1a infected patient. No sign of other resistance mutation was detected among samples.

The most frequent substitutions were determined as *I52M (N=9)*, *S102A (N=9)*, *S166A (8)* and *V170I (8)* for *genotype 3a*, and *F147S/A(4)* for *genotype 1*. However, some uncharacterized substitutions on scored position, including*I132L (N=1)*, *I170V (N=3)* and *N174S (N=2)* were also determined by *Geno2Pheno* assessment. Different types of variation were also detected by *geno2phen*o survey for *genotype 1*, among them *S7A(3)*, A66G (3), P86Q/A (3), K87A (3), V170I (3), were more prevalent. As well, in genotype 3a mutations including *A98T*(6),*A39T*(3) and *A67V* (3) were detected, as shown in [Table 2](#T2){ref-type="table"}.

*Phylogenetic Analysis*

The analysis of phylogenetic tree demonstrated a parallel result with nested-PCR findings. The constructed phylogenetic tree demonstrated that the sequence of each patient was correctly located in expected branch as belonged to relevant genotype. This finding showed that out of 14 samples, 2, 3 and 9 samples belonged to sub-genotypes 1a, 1b and 3a, respectively as shown in [Figure 2](#F2){ref-type="fig"}. These sequences were submitted to NCBI GenBank with accession numbers: MK609550-MK609563. The finding highlights the power of NS3 protease region for construction of a valid phylogenetic tree and further genetic analysis of virus.

Discussion
==========

Despite the availability of DAAs drugs for the treatment of HCV, natural mutation still remains a big challenge (Vermehren and Sarrazin, 2011; Paolucci et al., 2013; Martinez et al., 2017). The rate of PIs natural mutations reported being wide to conclude for all areas and genotypes (Vallet et al., 2005; Lopez-Labrador et al., 2008; Paolucci et al., 2012; Martinez et al., 2017; Morsica et al., 2017). Although there are a couple of reports regarding this issue around the world, in Iran limited publications have considered it.

Actually, the impact of some *PIs* resistance on *HCV DAAs* treatment should be considered as their occurrence before the starting of therapy may render resistance even when being treated with other *DAAs* (Paolucci et al., 2012; Lamb, 2017; Martinez et al., 2017; Morsica et al., 2017). Herein, *NS3* protease sequence of a small patient population that determined as non-responder to *Peg-IFN* plus Ribavirin treatment were analyzed. This was the second study that had been done in Iran and the results demonstrated a similar finding to a previous report on a DAAs treatment-naive population (Afrasiabi et al., 2015).

Herein, variations responsible for *PIs*resistance were investigated by sequencing assay. From characterized mutations, only one out of 14 samples (7%) harbored *R117C+N174S*double mutation, which could render it a reduced susceptibility phenotype to Telaprevir. However, no *PIs* resistance related substitution was detected among samples. The importance of this type of mutation and the effect on resistance to PIs has been mentioned by different studies (Patino-Galindo et al 2016, Paolucci et al., 2012). This type of mutation should be considered in a screening method before the start of *PIs* therapy for patients.

Besides, there were some uncharacterized mutations in samples including *V170I* (11 out of 14) and *I132L* (4 out of 14) and *N174S (N=2)* in both genotype 1 and 3. Some of these variations were determined as "uncharacterized substitutions on scored position" by Geno2pheno software, due to their possible but not immediate role in PIs resistance(Kalaghatagi et al,. 2016). These kinds of mutations may render partial resistant phenotype to some extent against different *PIs* drugs (Paolucci et al., 2012, Patino-Galindo et al 2016). Similarly, these mutations have been detected in association with major resistant mutations in some other studies, however, their exact role on resistance phenotype and virus fitness needs to be evaluated (Sargin Altunok et al., 2016; Zhang et al., 2016).

A couple of experiments reported the different rate of heterogeneity and pre-existing substitutions with the potential but of PIs resistance (Kuntzen et al., 2008; Lopez-Labrador et al., 2008; Vallet et al., 2011; Paolucci et al., 2012; Morsica et al., 2017). In one clonal sequencing based investigation, variation in the protease region of 17 patients with genotype-1 showed a noticeable amount of heterogeneity alongside the protease region (Vallet et al., 2005). Kuntzen et al., (2008) following sequence analysis the finding of a high frequency of PIs resistance mutations (near 8%) recommended a screening method of PIs resistance mutations before DAAs administration to reduce the cost and treatment failures. This data was supported by other regions such as Argentina (Jimenez-Sousa et al., 2016) even by the employment of traditional sequencing. The limited studies conducted in this regard in Iran indicated the presence of a critical *R155K* mutation among a very small population (1 out of 7) (Afrasiabi et al., 2015). However, there are some reports claiming the low frequency of major *PIs* resistance mutations in an infected population. Different reports from Europe like ones by Vallet and others detected a low frequency of PIs critical mutations by direct sequencing (Vallet et al., 2011; Jimenez-Sousa et al., 2016).

In addition, the most prevalent substitutions were determined as *I52M (N=9)*, *S102A (N=9)* and*S166A (8)*for *genotype 3a*, and *F147S/A (4)* for *genotype 1*. Whereas these kinds of polymorphisms were detected prevalently in other reports, their exact impacts on the protein function, virus fitness, and even drug susceptibility have to be defined (Paolucci et al., 2012).

The genotype determination of HCV confirmed to be reliable particularly when evaluated by analysis of *NS5A* gene (Dehghani-Dehej et al., 2017). However, other regions such as NS3 as an alternative candidate were taken into account by some other groups. As a candidate gene for genotyping purpose, it even showed a comparable sensitivity and specificity level with commercially available Versant HCV 2.0 reverse hybridization line-probe assay (LiPA 2.0) for subtyping assay (Neukam et al., 2017). In our experiment, it was also revealed that *NS3* protease region exhibits a reliable discriminative potential to differentiate between sub-*genotype 1a*, *1b*, and *3a*. The *NS3*-based phylogenetic tree and investigation in *Geno2Pheno*system truly revealed different sub-genotypes at relevant clusters, indicating the power of *NS3*to molecularly differentiate among them.

The present study has some limitations, including the small size of population, heterogeneous genotype distribution among enrolled patients and a few numbers of investigated clones for further analysis.

In conclusion, with the exception of *R117C+N174S*double mutation, confer a reduced susceptibility for Telaprevir, no sign of resistance mutation was found. Therefore, the low frequency of *PIs* resistance mutations is hopeful to start these medications for I*FN/RIB* non-responder patients. However, despite the relevant reports regarding the low frequency of PIs resistance, the cost and side effects should inspire us to develop simple methods of resistance screening for treatment failure prevention. In addition, the NS3 protease region could serve as a reliable region for construction of a phylogenetic tree.
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